Retinal Consultants Medical Group | Modesto, CA

Research site

(Unclaimed)

Location

4712 Stoddard Road Suite 180, Modesto, California, United States of America

Site insights

Top conditions

Top treatments

Faricimab

Aflibercept

EYE103

Ranibizumab

Tarcocimab

Pegcetacoplan

BI 771716

Runcaciguat

Parent organization

This site is a part of Retinal Consultants Medical Group

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 9 total trials

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME (BRUNELLO)

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active...

Enrolling

Diabetic Macular Edema (DME)

Drug: EYE103

Drug: Ranibizumab

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (...

Enrolling

Wet Age-related Macular Degeneration

Drug: Tarcocimab tedromer

Drug: Aflibercept

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) (GLOW2)

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.

Enrolling

Non-proliferative Diabetic Retinopathy

Drug: Tarcocimab

Other: Sham injection

New

A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy (VERDANT)

This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine ca...

Begins enrollment this month

Macular Degeneration, Age-related

Geographic Atrophy

Drug: Pegcetacoplan

Drug: Sham comparator to BI 771716

Safety and Efficacy of Faricimab in Patients With NPDR (MAGIC)

The purpose of this Phase 2 study is comprised of two groups to evaluate the safety, tolerability, and efficacy of faricimab in patients with Non-Pro...

Active, not recruiting

Non-Proliferative Diabetic Retinopathy

Drug: Faricimab